| TAH Drug Code | IOKM |
|---|---|
| Indications | Prevention of chemotherapy-induced nausea and vomiting. Prevention of postoperative nausea and vomiting. |
| Dosing | Chemotherapy-induced nausea and vomiting, associated with emetogenic chemotherapy; Prophylaxis: Adult: 0.25 mg IV over 30 seconds approximately 30 minutes prior to starting chemotherapy. Children and Adolescents (1 month to 17 years old): 20 mcg/kg IV over 15 minutes approximately 30 minutes prior to starting chemotherapy; maximum dose: 1.5 mg. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to palonosetron or any component of the formulation |
| Adverse Effects | Common Cardiovascular: Bradyarrhythmia (1% to 4% ); Gastrointestinal: Constipation (up to 5% ); Neurologic: Headache (up to 9% ) Serious Cardiovascular: Prolonged QT interval; Immunologic: Anaphylaxis, Hypersensitivity reaction; Neurologic: Seizure; Other: Serotonin syndrome |
| Pregnancy | No (Limited) Human Data – Animal Data Suggest Low Risk |
| Lactation | No (Limited) Human Data - Probably Compatible |
| More Info | UpToDate |